Asia FX weakens slightly, rupee recovers from record low as RBI holds rates
In a stark reflection of investor sentiment, Fluidigm Corp (NASDAQ:LAB)'s stock has tumbled to a 52-week low, touching a price level of just $0.98. According to InvestingPro data, the stock currently trades 65% below its 52-week high of $3.04, with a market capitalization of approximately $419 million. This latest price point underscores a period of significant bearish momentum for the company, which has seen its stock value erode by an alarming 61.11% over the past year. The steep decline has raised concerns among shareholders and market analysts alike, as Fluidigm grapples with the challenges that have led to this precipitous drop in its market valuation. InvestingPro analysis suggests the stock may be undervalued at current levels, with additional insights revealing the company maintains a strong current ratio of 5.7 despite rapidly burning through cash. Get access to 8 more exclusive ProTips and a comprehensive Pro Research Report covering what really matters about Fluidigm's financial health and future prospects.
In other recent news, Standard BioTools reported its fourth-quarter 2024 earnings, missing both earnings per share (EPS) and revenue forecasts. The company posted an EPS of -$0.09, falling short of the anticipated -$0.07, and recorded revenue of $46.7 million, slightly below the expected $47.02 million. This marks a 9% year-over-year decline in revenue for both the quarter and the full year, with full-year revenue totaling $175.1 million. KeyBanc analysts downgraded Standard BioTools from Overweight to Sector Weight due to revenue concerns for 2025, as the company provided guidance between $165 million and $175 million, below the consensus estimate of $186.9 million. The downgrade reflects apprehensions about potential budget cuts to the National Institutes of Health (NIH), which could affect the company's revenue from academic institutions. Despite the challenges, Standard BioTools has launched new products, including the SomaScan proteomics platform, aiming to capture a significant market opportunity. Additionally, a collaboration with Illumina (NASDAQ:ILMN) on a proteomics program is underway, although substantial commercial revenue from this partnership is not expected before 2026, according to KeyBanc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.